FANCD2OS

Across TCGA pan-cancer cohorts, FANCD2OS Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FANCD2OS data layer compared with 24 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher FANCD2OS Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FANCD2OS expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BRCA, BLCA, and SKCM are the cancer types where FANCD2OS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.363	0.925	<.001	36	view →
BLCA	OS	Median	All	0.141	0.687	.003	18	view →
SKCM	DFS	Median	All	1.000	0.615	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FANCD2OS–BRCA (OS)

Open the BRCA breakdown →